source
- Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
- New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warnA new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…